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NEURO-ONCOLOGY

EG-17. SUV420-MEDIATED HETEROCHROMATIN CHANGES IN
PEDIATRIC BRAIN CANCERS
Timothy E. Van Meter1,2, Jocelyn Terry2, Nathan Rockwell1, Sarah Goggin2,
Priya Nethala2, and Asadullah Khan1; 1VCU School of Medicine, Richmond,
VA, USAM; 2College of William and Mary, Williamsburg, VA, USA
Silencing mechanisms play a role in genomic stability by maintaining condensed, non-active regions of the genome. SUV420 enzymes contain a SET
domain conferring methyltransferase activity toward histones. The Histone
H4 lysine 20 trimethylation (H4K20me3) mark maintained by SUV420H2 is associated with heterochromatin formation and gene silencing, whereas the dimethylated mark (H4K20me2) is associated with DNA repair. In studies of
epigenetic factors in large patient cohorts with ependymoma, it was found
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that SUV420H2 expression was lost or diminished in patients with reciprocal
increases in prognostic markers such as hTERT. To better understand the
normal function of Suv4-20H1/H2 enzyme in neural progenitors, and pathological changes in cancers, a variety of differentiation paradigms were used.
The NT2D1 neurally restricted cell line, and BGO1V and H9 human embryonic
stem cells (ESCs), and differentiated progeny, were used alongside tumors to
better understand enzyme targets and functional outcomes (e.g.,lineage, differentiation, regional chromatin modifications). Lineage stages were verified with
stage-specific markers by immunofluorescence and qPCR. Suv4-20 H1 and H2
were present in ESCs and neural progenitors and decreased thereafter. RNAi
knockdown of SUV420 enzymes led to decreased H4K20 methylation in
cancer cells. DNA methylation microarrays and ChIP-PCR suggest 1) that
SUV420 is not regulated by DNA methylation in ependymomas; 2) that active
chromatin marks such as H3K4 dimethylation are enriched near the transcriptional start site in the SUV420H2 gene, and 3) that hTERT is hyper-methylated
at specific CpG islands and histones in a tumor sub-group-specific manner. This
data supports the hypothesis that Suv4-20H2 is highly active in progenitor cells
and functionally lost in some brain cancers. These studies begin to elucidate coincident mechanisms of gene silencing active in neural progenitors that may be
altered in a subset of pediatric brain cancers.

